Tiziana Life Sciences to present poster at ECTRIMS

Tiziana Life Sciences LTD filed a report stating that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), held September 24–26, 2025 in Barcelona, Spain.

Rhea-AI Filing Summary

Tiziana Life Sciences LTD filed a report stating that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), held September 24–26, 2025 in Barcelona, Spain. ECTRIMS is described as the world’s largest annual international conference focused on basic and clinical research in multiple sclerosis, bringing together leading scientists, clinicians, and industry partners.

The company’s press release with further details is furnished as Exhibit 99.1 to this report and is not incorporated by reference into other securities filings unless specifically referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tiziana Life Sciences (TLSA) report in this Form 6-K?

The company reported that it will present a scientific poster at the 41st ECTRIMS Congress, an international conference focused on multiple sclerosis research and treatment.

When and where is Tiziana Life Sciences (TLSA) presenting its scientific poster?

Tiziana Life Sciences will present at the 41st ECTRIMS Congress, held from September 24–26, 2025 in Barcelona, Spain.

What is the ECTRIMS Congress mentioned by Tiziana Life Sciences (TLSA)?

The ECTRIMS Congress is described as the world’s largest annual international conference dedicated to basic and clinical research in multiple sclerosis, bringing together scientists, clinicians, and industry partners.

Does this Tiziana Life Sciences (TLSA) 6-K include the full press release?

The report states that the press release is furnished as Exhibit 99.1. The exhibit contains further details and is provided with the Form 6-K.

Is the Tiziana Life Sciences (TLSA) ECTRIMS announcement considered filed for liability purposes?

The report states that the information in Exhibit 99.1 is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934.

Will the ECTRIMS announcement be automatically incorporated into other Tiziana Life Sciences (TLSA) SEC filings?

The document explains that the Exhibit 99.1 information is not deemed incorporated by reference into other filings unless specifically referenced in those filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/24/2025 - 08:30 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒  Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 24, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain. The ECTRIMS Congress is the world’s largest annual international conference dedicated to basic and clinical research in multiple sclerosis. It brings together leading scientists, clinicians, and industry partners to share the latest advances in MS research and treatment.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: September 24, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 24, 2025

3